Issuance of common shares on exercise of warrants (note 10) Proceeds from Issuance of Warrants Liability from in-licensing agreements Liabilities From-In-Licensing Agreements Liabilities From-In-Licensing Agreements Remaining unamortized compensation expense, weighted-average period Weighted-average contractual term, vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Computed taxes at United States statutory income tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount IPR&D Indefinite Lived Intangible Assets In Process Research and Development [Member] Information by major type or class of indefinite-lived intangible assets. In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process. Cover [Abstract] Cover [Abstract] Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Discount rate Measurement Input, Discount Rate [Member] Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Trading Symbol Trading Symbol Non-NEOs Non-NEOs [Member] Operating lease right-of-use assets Deferred Tax Liabilities Operating lease right-of-use assets Deferred tax liabilities, operating lease right-of-use assets . Disposal Group Name [Domain] Disposal Group Name [Domain] Cash Equivalents Cash Equivalents [Member] Accounts receivable Increase (Decrease) in Accounts Receivable Net income (loss) per share Earnings Per Share, Policy [Policy Text Block] Tax credit carryforward, amount not subject to expiration Tax Credit Carryforward, Not Subject To Expiration Tax Credit Carryforward, Not Subject To Expiration Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Issuance of common shares upon vesting of restricted stock units ("RSUs") (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Proceeds from stock options exercised Proceeds from Stock Options Exercised Unrealized (loss) income on available for sale securities, net of tax of nil (note 5) OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Award Timing Disclosures [Line Items] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Rolling Year Five Goods and services tax payable Sales and Excise Tax Payable, Current Proceeds from marketable securities Proceeds from Sale and Maturity of Marketable Securities Clinical Trial Expense Accruals Clinical Trial Expense Accruals [Policy Text Block] Clinical Trial Expense Accruals. Collaborative agreement expansion fee Collaborative Agreement Expansion Fee Collaborative agreement expansion fee. Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Segment Information Segment Reporting, Policy [Policy Text Block] Share issued, price per share (in dollars per share) Sale of Stock, Price Per Share Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Acquired In-Process Research and Development (IPR&D) and Definite-lived Intangible Assets Acquired In Process Research And Development And Definite Lived Intangible Assets [Policy Text Block] Acquired In Process Research And Development And Definite Lived Intangible Assets. Leases [Abstract] Leases [Abstract] Finite-lived intangible assets, gross Finite-Lived Intangible Assets, Gross Adjustments to prior year Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount Net cash (used in) / provided by operating activities Net Cash Provided by (Used in) Operating Activities ZW191 ZW191 [Member] ZW191 Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Property and equipment Deferred Tax Assets, Property, Plant and Equipment Weighted assessment of the likelihood of the milestones Measurement Input, Likelihood Of Milestones [Member] Measurement Input, Likelihood Of Milestones Award Timing Method Award Timing Method [Text Block] Office equipment Office Equipment [Member] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Moore [Member] Moore Derivative liability, classified stock options and ESPP Derivative Liability, Classified Stock Options and ESPP Derivative Liability, Classified Stock Options and ESPP Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Royalty payments on future global net sales (up to) Percentage of Royalty Rate Payments Percentage of royalty rate payments. ZW25 Agreement ZW25 Agreement [Member] ZW25 Agreement. Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional paid-in capital Additional Paid in Capital, Common Stock Payables and Accruals [Abstract] Payables and Accruals [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Company Selected Measure Amount Company Selected Measure Amount Celgene Celgene [Member] Celgene. Tabular List, Table Tabular List [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Class of warrant or right, pre-funded (in shares) Class of Warrant or Right, Pre-Funded Pre funded warrants issued in lieu of common shares to underwriters. Long-term marketable securities: Debt Securities, Available-for-Sale, Amortized Cost [Abstract] Amounts paid or transferred to payables Contingent Consideration Liability Fair Value Disclosure, Transfers Contingent Consideration Liability Fair Value Disclosure, Transfers Weighted average remaining lease term: Weighted Average Remaining Lease Term [Abstract] Weighted Average Remaining Lease Term Options vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Goodwill (note 6) Goodwill Share repurchase program, authorized amount Share Repurchase Program, Authorized, Amount Weighted average discount rate: Weighted Average Discount Rate [Abstract] Weighted Average Discount Rate Recognition of licensing and technology transfer fee Licensing And Technology Transfer Fee [Member] Licensing And Technology Transfer Fee Share-based Payment Arrangement, Option Share-based Payment Arrangement, Option Share-Based Payment Arrangement, Option [Member] Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Depreciation of property and equipment (note 7) Depreciation expense Depreciation Investments, cost Debt Securities And Equity Securities Without Readily Determinable Fair Value, Cost Debt Securities And Equity Securities Without Readily Determinable Fair Value, Cost Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures License Option License [Member] Number of agreements Number Of Agreements Number Of Agreements Comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Income tax payable (note 13) Accrued Income Taxes, Current Award Type [Axis] Award Type [Axis] Award Type [Axis] Net deferred tax (liabilities) assets Deferred Tax Liabilities, Net Corporate debt securities Corporate Debt Securities [Member] Exchange of shares per the Redomiciliation (in shares) Temporary Equity, Stock Issued During Period, Shares, New Issues Temporary Equity, Stock Issued During Period, Shares, New Issues Other Other Accrued Liabilities, Noncurrent Property and equipment, net (note 7) Property and equipment, net Property, Plant and Equipment, Net ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Total liabilities Liabilities Investment tax credits Investment Tax Credit Carryforward [Member] Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Acquired Indefinite-lived Intangible Assets [Line Items] Acquired Indefinite-Lived Intangible Assets [Line Items] Research Milestone Research Milestone [Member] Research Milestone [Member] Number of reporting units Number of Reporting Units Common stock, par value per share (in dollars per share) Common Stock, Par or Stated Value Per Share Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Class of warrant or right, number of securities called by each warrant or right (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Current portion of operating lease liability (note 14) Current portion Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Guaranteed investment certificates (“GICs”) and mutual funds GICs and mutual funds Guaranteed Investment Contract [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Canada, Dollars Canada, Dollars Net operating loss carry forwards Deferred Tax Assets, Operating Loss Carryforwards Subsequent Event [Line Items] Subsequent Event [Line Items] Property and equipment Property, Plant and Equipment, Gross Issuance of common shares on exercise of stock options (note 10e) (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development expense Research and Development Expense [Member] Weighted- Average Exercise Price ($) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Cash Cash [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted (in shares) Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Iconic Therapeutics Inc Iconic Therapeutics Inc [Member] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Other research and development expense Other Research and Development Expense Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Gross deferred tax assets Deferred Tax Assets, Gross Research, Collaboration and Licensing Agreements Collaborative Arrangement Disclosure [Text Block] Accumulated Impairment Indefinite-lived Intangible Assets Accumulated Impairment [Roll Forward] Indefinite-lived Intangible Assets Accumulated Impairment Debt securities, fair value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One First Phase 2 Trial First Phase 2 Trial [Member] First Phase 2 Trial Research Agreement Product Four Research Agreement Product Four [Member] Research Agreement Product Four Costs for in-progress software implementations Software and Software Development Costs [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Schedule of Changes in Fair Value of the Company's Liability for Contingent Consideration Changes In Fair Value Of Contingent Consideration [Table Text Block] Changes In Fair Value Of Contingent Consideration [Table Text Block] Sale of Stock [Domain] Sale of Stock [Domain] Change during the period Indefinite-Lived Intangible Assets Accumulated Amortization Indefinite-Lived Intangible Assets Accumulated Amortization Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Adjustment for dilutive effect of equity classified stock options and RSUs (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Weighted-average contractual term, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Outstanding at beginning of period (in shares) Outstanding, at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Document Type Document Type Tax Year 2036 Tax Year Two Thousand Thirty Six [Member] Tax Year Two Thousand Thirty Six [Member] Tax Year 2038 Tax Year Two Thousand Thirty Eight [Member] Tax Year Two Thousand Thirty Eight [Member] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Software Computer software Computer Software, Intangible Asset [Member] Purchases of marketable securities Payments to Acquire Marketable Securities First Phase 3 Trial First Phase 3 Trial [Member] First Phase 3 Trial Weighted-average contractual term, exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Stock options Deferred Tax Assets Stock Options Deferred Tax Assets Stock Options Liability for contingent consideration (note 15) Business Combination, Contingent Consideration, Liability, Noncurrent Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Subsequent Event [Table] Subsequent Event [Table] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Maximum Maximum [Member] Federal Tax Incentive Federal Tax Incentive [Member] federal tax incentive [Member] Debt securities, fair value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, After Year Three Through Four Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, After Year Three Through Four Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Furniture and fixtures Furniture and Fixtures [Member] Intangible assets, net (note 8) Intangible assets, net Finite-Lived Intangible Assets, Net Investment Type [Axis] Investment Type [Axis] Research licenses Research Licenses [Member] Research Licenses Share issued price per share (in dollars per share) Shares Issued, Price Per Share Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Schedule of Estimated Fair Value of Stock Options Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Operating lease expense Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] (Loss) income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Royalty term Collaborative Arrangement, Royalty Term Collaborative Arrangement, Royalty Term Contractual maturity of one year or less: Debt Securities, Available-For-Sale Fiscal Year Maturity, Year One [Abstract] Debt Securities, Available-For-Sale Fiscal Year Maturity, Year One Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Name Outstanding Recovery, Individual Name Variable lease expense Variable Lease, Cost Goodwill, impairment loss Goodwill, Impairment Loss Collaborative arrangement, number of products Collaborative Arrangement, Number Of Products Collaborative Arrangement, Number Of Products Debt securities, fair value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, After Year One Through Three Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, After Year One Through Three Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Other general and administrative expense Other General and Administrative Expense Options forfeited and cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares Diluted (in dollars per share) Net (loss) income per common share – diluted (in dollars per share) Earnings Per Share, Diluted Counterparty Name [Domain] Counterparty Name [Domain] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Deferred revenue and other consideration Increase (Decrease) in Contract with Customer, Liability Current income tax expense Current Income Tax Expense (Benefit) Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Schedule of Expiry Details of Investment Tax Credits, Non-Capital Losses and Net Operating Losses for Income Tax Purposes Summary Of Operating Loss And Tax Credit Carryforwards [Table Text Block] Summary Of Operating Loss And Tax Credit Carryforwards [Table Text Block] Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Foreign exchange gain (loss) Gain (Loss), Foreign Currency Transaction, before Tax Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] LEO Pharma Leo Pharma [Member] Leo Pharma. Statement of Financial Position [Abstract] Merck Sharp and Dohme Research Ltd. Merck Sharp and Dohme Research Ltd. [Member] Merck sharp and dohme research ltd. Proceeds from collaboration agreement Payment Received On Collaboration Agreement Payment Received On Collaboration Agreement Acquired IPR&D, beginning balance Acquired IPR&D, ending balance Acquired In Process Research And Development Acquired in Process Research and Development. Schedule Of Accounting Policies [Table] Schedule Of Accounting Policies [Table] Schedule of accounting policies. Changes due to SR&ED and research credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Other Deferred Tax Liabilities, Other Income tax (expense) recovery (note 13) Income tax expense Income tax (expense) recovery, net Income Tax Expense (Benefit) Other income: Nonoperating Income (Expense) [Abstract] Liability for contingent consideration Liability for Contingent Consideration [Member] Liability for contingent consideration. Nonvested award, cost not yet recognized, period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Research and development collaborations (note 11) Research and development collaborations Revenue from Contract with Customer, Excluding Assessed Tax Acquisition of intangible assets Payments to Acquire Intangible Assets Accounts Receivable and Expected Credit Losses Accounts Receivable And Expected Credit Losses [Policy Text Block] Accounts Receivable And Expected Credit Losses Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Net cash provided by / (used in) investing activities Net Cash Provided by (Used in) Investing Activities Private placement (note 10a) Proceeds from Issuance of Private Placement Number of additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized All Adjustments to Compensation All Adjustments to Compensation [Member] Employee compensation and related accruals Employee-related Liabilities, Current Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Development Milestone Development Milestone [Member] Development milestone. Schedule of Other Income (Expense) Nonoperating Schedule of Other Nonoperating Income (Expense) [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Interest income Interest Income (Expense), Nonoperating Collaborative arrangement, maximum regulatory milestone payments Collaborative Arrangement, Maximum Regulatory Milestone Payments Collaborative Arrangement, Maximum Regulatory Milestone Payments Scenario [Domain] Scenario [Domain] Issuance of common stock upon vesting of RSUs (note 10f) Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Debt securities, amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, After Year Three Through Four Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, After Year Three Through Four Entity Address, State or Province Entity Address, State or Province Research, Development, Commercial License Option Milestone Research And Development Regulatory And Sales Related Milestone [Member] Research and development regulatory and sales related milestone. Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Trade payables Accounts Payable, Trade, Current Financial Instruments [Domain] Financial Instruments [Domain] Tax Year 2037 Tax Year Two Thousand Thirty Seven [Member] Tax Year Two Thousand Thirty Seven [Member] Outstanding, at beginning of period (in dollars per shares) Outstanding, at end of period (in dollars per shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Arrangement Other than Collaborative Arrangement Other than Collaborative [Member] Maximum milestone payments and tiered royalties Collaborative Arrangement, Maximum Milestone Payments and Tiered Royalties Collaborative Arrangement, Maximum Milestone Payments and Tiered Royalties Galbraith [Member] Galbraith Restatement Determination Date Restatement Determination Date Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Royalty percentage earned from sales of product Royalty Percentage Earned From Product Sales Royalty percentage earned from product sales. Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Schedule of Marketable Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease right-of-use assets (note 14) Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Number of liability classified stock options outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Currency [Axis] Currency [Axis] Acquired IPR&D Indefinite-lived Intangible Assets Acquired [Roll Forward] Indefinite-lived Intangible Assets Acquired Schedule of Financial Liabilities Measured at Fair Value on a Recurring Basis Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Temporary Equity, by Class of Stock [Table] Temporary Equity, by Class of Stock [Table] Financial liabilities measured at fair value Financial Liabilities Fair Value Disclosure Net (Loss) Income per Share Earnings Per Share [Text Block] Issuance of common stock through employee stock purchase plan (note 10g) Stock Issued During Period, Value, Employee Stock Purchase Plan Subsequent Event Subsequent Event [Member] Research Agreement Product Two Research Agreement Product Two [Member] Research Agreement Product Two Beginning balance Ending balance Indefinite Lived Intangible Assets Impairment Indefinite Lived Intangible Assets Impairment Issuance of common stock on exercise of stock options (note 10f) Stock Issued During Period, Value, Stock Options Exercised Milestone Payment Milestone Payment [Member] Milestone payment [member] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Income Taxes Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Research Agreement Product Three Research Agreement Product Three [Member] Research Agreement Product Three Segments [Domain] Segments [Domain] Cross License Agreement Cross License Agreement [Member] Cross license agreement. Unrecognized Tax Benefits [Roll Forward] Unrecognized Tax Benefits [Roll Forward] Schedule of Repurchase Agreements Schedule of Repurchase Agreements [Table Text Block] 3 to 4 years Lessee, Operating Lease, Liability, to be Paid, Rolling Year Four License and Collaboration License and Collaboration [Member] License and Collaboration PEO PEO [Member] Increase (decrease) in fair value of liability for contingent consideration Contingent Consideration Fair Value Adjustments Contingent consideration fair value adjustments. Deferred Tax Asset [Domain] Deferred Tax Asset [Domain] Name Trading Arrangement, Individual Name Weighted-average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Entity Public Float Entity Public Float Disposal Group Name [Axis] Disposal Group Name [Axis] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Number of common shares reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Number of renewal options Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Deferred tax assets liabilities before valuation allowance Deferred Tax Assets Liabilities Before Valuation Allowance Deferred tax assets (liabilities) before valuation allowance. Less: valuation allowance Deferred Tax Assets, Valuation Allowance Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Weighted- Average Contractual Term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Changes in non-cash operating working capital: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Percentage of discounted purchase price of average market price Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Debt securities, available-for-sale, excluding accrued interest Debt Securities, Available-for-Sale, Excluding Accrued Interest Investments, fair value Debt Securities And Equity Securities Without Readily Determinable Fair Value Debt Securities And Equity Securities Without Readily Determinable Fair Value Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Long-term marketable securities (note 5) Debt Securities, Available-for-Sale, Excluding Accrued Interest, Noncurrent Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Recognition of licensing fee Licensing Fee [Member] Licensing Fee Common stock Common Stock [Member] 1 to 2 years Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Segment Reporting [Abstract] ZW251 ZW251 [Member] ZW251 Entity Central Index Key Entity Central Index Key Scenario [Axis] Scenario [Axis] General and administrative expense General and Administrative Expense [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Commercial Sales Milestones Commercial Sales Milestones [Member] Commercial Sales Milestones [Member] United States of America, Dollars United States of America, Dollars Stockholders' Equity Equity [Text Block] Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Financial Instrument [Axis] Financial Instrument [Axis] Business Segments Segment Reporting Disclosure [Text Block] Recent Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Adjustment for dilutive effect of liability classified stock options (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements, Liability Classified Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements, Liability Classified Title Trading Arrangement, Individual Title Research Agreement Product One Member Research Agreement Product One Member [Member] Research Agreement Product One Member Balance, beginning of year Balance, end of year Unrecognized Tax Benefits City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Auditor Location Auditor Location Investments Investments [Member] Contingent liability Business Combination, Contingent Consideration, Liability Accrued legal, professional fees and other Accrued Legal And Professional Fees, Current Accrued legal and professional fees, current. Laboratory equipment Laboratory Equipment [Member] PropertyPlantAndEquipmentByTypeAxis=zyme Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Variable consideration commercial milestone payments amount Revenue, Remaining Performance Obligation, Variable Consideration Commercial Milestone Payments Amount Revenue, Remaining Performance Obligation, Variable Consideration, Commercial Milestone Payments, Amount Preferred stock Preferred Stock [Member] Business Combination and Goodwill Business Combinations And Goodwill [Policy Text Block] Business Combinations And Goodwill. Purchases of common stock for retirement (note 10c) Payments for Repurchase of Common Stock Exchangeable shares Exchangeable Shares [Member] Exchangeable Shares Collaborative arrangement, maximum commercial milestone payments Collaborative Arrangement, Maximum Commercial Milestone Payments Collaborative Arrangement, Maximum Commercial Milestone Payments Research, Development and Commercial Milestones Research, Development and Commercial Milestones [Member] Research, development and commercial milestones member Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Commercial Milestones Commercial Milestones [Member] Commercial milestones. Schedule of Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Weighted- average grant date fair value ($) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted average estimated period for achievement of milestones Measurement Input, Expected Term [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Cash, Cash Equivalents and Marketable Securities Investment [Text Block] Net (loss) income per common share (note 4): Earnings Per Share [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) Schedule of Non-Vested Stock Option Activity Schedule of Nonvested Share Activity [Table Text Block] Class of Stock [Domain] Class of Stock [Domain] Contractual maturity of one to three years: Debt Securities, Available-For-Sale Fiscal Year Maturity, Year One Through Three [Abstract] Debt Securities, Available-For-Sale Fiscal Year Maturity, Year One Through Three Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] General and administrative General and Administrative Expense Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Total operating lease liabilities Total operating lease liabilities Operating Lease, Liability Underlying Securities Award Underlying Securities Amount Termination fee Lessee, Operating Lease, Termination Fee Lessee, Operating Lease, Termination Fee Vested and settled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Individual penalty, threshold percentage Share-Based Payment Arrangement, Individual Penalty, Threshold Percentage Share-Based Payment Arrangement, Individual Penalty, Threshold Percentage Long-term prepaids and other assets Prepaid Expense and Other Assets, Noncurrent Number of potential products to developed and commercialized Number of potential products developed and commercialized Number of potential products developed and commercialized. Amendment Flag Amendment Flag Adjustment for change in fair value of liability classified stock options Fair Value, Option, Adjustment For Change In Fair Value Of Liability Classified Stock Options Fair Value, Option, Adjustment For Change In Fair Value Of Liability Classified Stock Options Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Offering Offering [Member] Offering. Subsequent Events [Abstract] Subsequent Events [Abstract] Tax Year 2040 Tax Year 2040 [Member] Tax Year 2040 Other Income (Expense), net Other Income and Other Expense Disclosure [Text Block] Number of common shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Debt securities, amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Non-vested, beginning balance (in shares) Non-vested, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Schedule of Carrying Value of IPR&D, Net of Impairment Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Short-term marketable securities (note 5) Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Canadian Dollar Under the New Option Stock Plan CAD Dollars Under The New Stock Option Plan [Member] CAD dollars under the new stock option plan. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Change during the period Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Auditor Name Auditor Name Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Property and equipment useful lives Property, Plant and Equipment, Useful Life Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Employee Stock Employee Stock [Member] Unamortized compensation expense related to unvested options Share Based Compensation By Share Based Payment Award Unamortized Compensation Expense Share based compensation by share based payment award unamortized compensation expense. Bristol-Myers Squibb Bristol-Myers Squibb [Member] Bristol-Myers Squibb Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Deferred revenue Deferred Tax Assets, Deferred Income Finance lease payments Finance Lease, Principal Payments Stock options Deferred Tax Liabilities, Stock Options Deferred Tax Liabilities, Stock Options Basic Net Income (Loss) Available to Common Stockholders, Basic Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Weighted-average common stock outstanding (note 4): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Total assets Assets ZW220 ZW220 [Member] ZW220 Delivery of Licenses, Initial Technology Transfer and BTC Data Transfer Delivery Of Licenses, Initial Technology Transfer And BTC Data Transfer [Member] Delivery Of Licenses, Initial Technology Transfer And BTC Data Transfer Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment Other long-term liabilities (note 9) Other Liabilities, Noncurrent Shares granted with respect to maximum fixed amount equal, percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Beginning balance Ending balance Indefinite Lived Intangible Accumulated Amortization Indefinite Lived Intangible Accumulated Amortization Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (note 15) Commitments and Contingencies Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Debt securities, unrealized gain (loss) Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Maturity, Allocated and Single Maturity Date, After Year One Through Three Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Maturity, Allocated and Single Maturity Date, After Year One Through Three Research and License Agreement Research and License Agreement [Member] Research and license agreement. Termination Date Trading Arrangement Termination Date Tax Year 2041 Tax Year 2041 [Member] Tax Year 2041 Nature of Operations Nature of Operations [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Income Tax Disclosure [Line Items] Income Tax Disclosure [Line Items] Income Tax Disclosure [Line Items] Deferred tax assets: Deferred Tax Assets, Gross [Abstract] Number of shares issued to underwriters (in shares) Stock Issued During Period, Shares, Issued for Services Contractual maturity of three to four years: Debt Securities, Available-For-Sale, Fiscal Year Maturity, Years Three Through Four [Abstract] Debt Securities, Available-For-Sale, Fiscal Year Maturity, Years Three Through Four Tax Year 2044 Tax Year 2044 [Member] Tax Year 2044 Net (loss) income Net income (loss) Net (loss) income Net Income (Loss) Attributable to Parent Total other income, net Other Operating Income (Expense), Net Trading Arrangement: Trading Arrangement [Axis] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Entity File Number Entity File Number Income Statement [Abstract] Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Weighted-average common stock outstanding: Weighted Average Number of Shares Outstanding, Basic [Abstract] Name Forgone Recovery, Individual Name Aggregate intrinsic value exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Operating leases Operating Lease, Weighted Average Remaining Lease Term Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Deferred income tax expense (recovery) (note 13) Increase (Decrease) in Deferred Income Taxes Zymeworks BC Inc Zymeworks BC Inc [Member] Zymeworks BC Inc Investments Investment, Policy [Policy Text Block] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Aggregate intrinsic value ($) Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value Contract assets Contract with Customer, Asset, after Allowance for Credit Loss Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Purchase and retirement of common stock (10c) Treasury Stock, Retired, Cost Method, Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Tax Year 2043 Tax Year 2043 [Member] Tax Year 2043 The Redomicile Transactions (note 1, note 10b) Stock Issued During Period, Value, Exchange Of Shares Per The Redomiciliation Stock Issued During Period, Value, Exchange Of Shares Per The Redomiciliation Adjustment to Compensation: Adjustment to Compensation [Axis] Accounts Receivable Accounts Receivable [Member] Fair value of consideration allocated to a group of contracts that were considered as a single contract Fair Value Of Consideration Allocated, Group Of Contracts Fair value of consideration allocated to a group of contracts that were considered as a single contract. Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Tax Year 2042 Tax Year 2042 [Member] Tax Year 2042 Name Awards Close in Time to MNPI Disclosures, Individual Name Construction in progress Construction in Progress [Member] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Filer Category Entity Filer Category Beginning balance (in shares) Ending balance (in shares) Shares, Issued Private Placement Private Placement [Member] GSK: GSK [Member] GSK Statistical Measurement [Domain] Statistical Measurement [Domain] Schedule of Cost Components of Operating Leases Lease, Cost [Table Text Block] Deferred Financing Fees Deferred Financing Costs [Policy Text Block] Deferred Financing Costs Policy Text Block. Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Schedule of Net (Loss) Income per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Tax credit carryforward, amount subject to expiration Investment tax credits Tax Credit Carryforward, Amount Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Net cash paid during the year for income taxes Income Taxes Paid, Net Other Commitments [Line Items] Other Commitments [Line Items] Issuance of common stock upon exercise of pre-funded warrants (note 10c) (in shares) Issuance of common shares upon exercise of pre-funded warrants (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount License Agreement License Agreement Terms [Member] Issuance of common stock for retracted exchangeable shares Conversion of Stock, Amount Converted Tax Year 2034 Tax Year Two Thousand Thirty Four [Member] Tax Year Two Thousand Thirty Four [Member] Other Performance Measure, Amount Other Performance Measure, Amount Research tax credits Research Tax Credit Carryforward [Member] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Leases Lessee, Operating Leases [Text Block] Common shares, outstanding (in shares) Common Stock, Shares, Outstanding Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Operating lease expense Operating Lease, Cost Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Long-term portion of operating lease liability (note 14) Long-term portion Operating Lease, Liability, Noncurrent Upfront Fee Upfront Fee [Member] Upfront Fee Investments, All Other Investments [Abstract] Investments, All Other Investments [Abstract] Deferred revenue and other consideration (note 11) Contract liabilities Contract with Customer, Liability, Current Entity Tax Identification Number Entity Tax Identification Number Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] Increases related to prior year tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Treasury stock repurchased (in shares) Treasury Stock, Shares, Acquired Money market funds Money Market Funds [Member] Accumulated Amortization Indefinite-lived Intangible Assets Accumulated Amortization [Roll Forward] Indefinite-lived Intangible Assets Accumulated Amortization Net proceeds from issuance Sale of Stock, Consideration Received on Transaction U.S. Treasury notes U.S. Treasury notes US Treasury Securities [Member] Zanidatamab Zymeworks Zanidatamab Inc. [Member] Zymeworks Zanidatamab Inc. Equity Components [Axis] Equity Components [Axis] Commission expense on share repurchases Share Repurchase Program, Commission Expense Share Repurchase Program, Commission Expense Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Total operating expenses Costs and Expenses Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Tax Year 2031 Tax Year Two Thousand Thirty One [Member] Tax Year Two Thousand Thirty One [Member] Platform Technology Transfer and License Agreement Platform Technology Transfer and License Agreement [Member] Platform technology transfer and license agreement. Aggregate intrinsic value outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Investments [Domain] Investments [Domain] Option Exercise Fee Option Exercise Fee [Member] Option Exercise Fee [Member] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Geographical [Axis] Geographical [Axis] Maximum exercise fees and milestone payments Collaborative Arrangement, Maximum Exercise Fees and Milestone Payments Collaborative Arrangement, Maximum Exercise Fees and Milestone Payments Net deferred tax (liabilities) assets Deferred Tax Assets, Net Other drug supply Drug Supply [Member] Drug Supply Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Liability for contingent consideration (note 15) Business Combination, Contingent Consideration, Liability, Current Warrants issued to purchase shares (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Issuance of common shares through employee share purchase plan (note 10f) (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Royalty agreement term Royalty Agreement Term Royalty agreement term. Tax Year 2030 Tax Year Two Thousand Thirty [Member] Tax Year Two Thousand Thirty [Member] Number of operating programs Number Of Operating Programs Number Of Operating Programs Non-capital losses carried forward Deferred Tax Assets Non-Capital Loss Carry Forwards Deferred Tax Assets Non-Capital Loss Carry Forwards 4 to 5 years Lessee, Operating Lease, Liability, to be Paid, Rolling Year Five Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Expected income tax rate Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent Nonvested award, cost not yet recognized, amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Milestone revenue Milestone Revenue [Member] Milestone Revenue Warrants exercised during period (in shares) Warrants Exercised During Period Warrants Exercised During Period Current assets: Assets, Current [Abstract] Future operating lease payments Operating Leases, Future Minimum Payments Receivable Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Tax Year 2029 Tax Year Two Thousand Twenty Nine [Member] Tax Year Two Thousand Twenty Nine [Member] Portion of fee received Option Fee, Portion Of Fee Received Option Fee, Portion Of Fee Received Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Schedule of Estimated Useful Lives Schedule Of Property Plant And Equipment Estimated Useful Lives [Table Text Block] Schedule Of Property Plant And Equipment Estimated Useful Lives [Table Text Block]. Product and Service [Domain] Product and Service [Domain] Vested and settled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Drug supply for ongoing studies Drug Supply For Ongoing Studies [Member] Drug Supply For Ongoing Studies Warrants issued price per pre funded warrant (in dollars per share) Warrants Issued, Price Per Pre Funded Warrant Warrants issued price per pre funded warrant. Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Total shares authorized (in shares) All Classes Of Stock, Shares Authorized All Classes Of Stock, Shares Authorized Contingent consideration Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies Options granted under original plan exercisable period Share Based Compensation Arrangement By Share Based Payment Award Exercisable Period Share Based Compensation Arrangement By Share Based Payment Award Exercisable Period Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Salaries and benefits Labor and Related Expense Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development expense Research and Development Expense Number of RSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Common shares, issued (in shares) Common Stock, Shares, Issued Income taxes payable Increase (Decrease) in Income Taxes Payable Entity [Domain] Entity [Domain] Finance lease liabilities: Finance Lease, Liability [Abstract] Concentration risk, percentage Concentration Risk, Percentage Other comprehensive income: Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent, Parenthetical Disclosure [Abstract] Fair value of liability classified stock options Derivative Liability Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Royalty percentage earned from sales of product (up to) Revenue, Remaining Performance Obligation, Variable Consideration, Royalty Percentage Royalty percentage earned from product sales. Net Indefinite-Lived Intangible Assets [Roll Forward] Valuation Allowance by Deferred Tax Asset [Axis] Valuation Allowance by Deferred Tax Asset [Axis] Zanidatamab zovodotin Zanidatamab zovodotin [Member] Zanidatamab zovodotin British Columbia BRITISH COLUMBIA Common stock, shares authorized (in shares) Common Stock, Shares Authorized Variable consideration option exercise fees and milestone payments amount Revenue, Remaining Performance Obligation, Variable Consideration Option Exercise Fees And Milestone Payments Amount Revenue, Remaining Performance Obligation, Variable Consideration, Option Exercise Fees And Milestone Payments Amount Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Exchangeable stock, shares issued (in shares) Exchangeable Shares, Issued Exchangeable Shares, Issued Entity Voluntary Filers Entity Voluntary Filers Operating lease liabilities: Operating Lease, Liability [Abstract] Deferred financing fees Payments Of Deferred Financing Fees The amount of costs incurred as part of equity financing transactions that have been paid. Renewal term Lessee, Operating Lease, Renewal Term Deferred income tax (expense) recovery Deferred Income Tax Expense (Benefit) Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Number of common shares issued (in shares) Redomicile Transaction, Number Of Shares Issued Redomicile Transaction, Number Of Shares Issued Total other comprehensive (loss) income Other comprehensive income (loss), Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Granted (in shares) Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] License Agreements Research Collaborations And Development Agreements [Abstract] License Agreements Research Collaborations And Development Agreements [Abstract] License Agreements Research Collaborations And Development Agreements Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Average price paid per share ( in usd per share) Shares Acquired, Average Cost Per Share Document Annual Report Document Annual Report Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Acquired in-process research and development assets (“IPR&D”) (note 6) Beginning balance Ending balance Indefinite-Lived Intangible Assets (Excluding Goodwill) Amortization of intangible assets (note 8) Amortization expense on intangible assets Amortization of Intangible Assets Contract liabilities Contract with Customer, Liability Audit Information [Abstract] Audit Information Accounting Policies [Abstract] Accounting Policies [Abstract] Revenue: Revenues [Abstract] Leasehold improvements Leasehold Improvements [Member] Current Fiscal Year End Date Current Fiscal Year End Date Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Atreca: Atreca [Member] Atreca PEO Name PEO Name Warrants outstanding (in shares) Class of Warrant or Right, Outstanding Award Type [Domain] Award Type [Domain] Award Type [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Deferred tax asset (note 13) Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Definite-lived intangible assets, useful life Finite-Lived Intangible Asset, Useful Life Additional paid-in capital Additional Paid-in Capital [Member] Finance lease liability (note 14) Long-term portion included in other long-term liabilities Finance Lease, Liability, Noncurrent Collaborative Arrangement Collaborative Arrangement [Member] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Option fee, one time fee Option Fee, One Time Fee Received Option Fee, One Time Fee Received Recent accounting pronouncements adopted and Recent accounting pronouncements not yet adopted New Accounting Pronouncements, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Less accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Amortization and impairment of operating lease right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Liability Classified Stock Options Liability Classified Stock Options [Member] Liability classified stock options. Number of operating segments Number of Operating Segments Unrealized foreign exchange gain Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Non-vested, beginning balance (in dollars per share) Non-vested, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Business combination, contingent consideration, liability, measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Stock-based compensation (note 10f) Share-Based Payment Arrangement, Noncash Expense Exchangeable shares, shares outstanding (in shares) Exchangeable Shares, Outstanding Exchangeable Shares, Outstanding Deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Percentage of royalty reduction Percentage of Royalty Reduction Percentage of Royalty Reduction Private placement (note 10a and 10d) Adjustments to Additional Paid in Capital, Warrant Issued Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Reportable Segment Reportable Segment [Member] Reportable Segment Diluted Net Income (Loss) Available to Common Stockholders, Diluted Change during the period Indefinite-Lived Intangible Assets, Period Increase (Decrease) Research and development deductions and credits Deferred Tax Asset, In-Process Research and Development Other income (expense), net (note 12) Total other income, net Nonoperating Income (Expense) Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Auditor Firm ID Auditor Firm ID (Loss) income from operations Segment (loss) income Operating Income (Loss) Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Research and development Research and Development Expense (Excluding Acquired in Process Cost) Total liabilities and stockholders’ equity Liabilities and Equity Subsequent event Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Impairment loss Operating Lease, Impairment Loss BeiGene: Bei Gene Bei Gene [Member] Bei Gene [Member] Intangible assets, net Finite-Lived Intangible Asset, Expected Amortization Finite-Lived Intangible Asset, Expected Amortization Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Leased assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Measurement Input Type [Axis] Measurement Input Type [Axis] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Individual: Individual [Axis] Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items] Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items] Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items] Computer hardware Computer Hardware [Member] Computer Hardware [Member] Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expected average option term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Product and Service [Axis] Product and Service [Axis] Contract assets and liabilities Contract Assets And Contract Liabilities [Policy Text Block] Contract assets and contract liabilities. Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Measurement Input Type [Domain] Measurement Input Type [Domain] Unrealized loss on available for sale securities, tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax License and Milestone Payments License and Milestone Payments [Member] License and milestone payments [member] Operating expenses: Operating Expenses [Abstract] Debt securities, unrealized gain (loss) Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Maturity, Allocated and Single Maturity Date, After Year Three Through Four Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Maturity, Allocated and Single Maturity Date, After Year Three Through Four Schedule of Components of Property and Equipment Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Description of payment terms Revenue, Performance Obligation, Description of Payment Terms Employees Stock Purchase Plan Employees Stock Purchase Plan [Member] Employees Stock Purchase Plan [Member] Government Grants and Credits Government Grants And Tax Credits [Policy Text Block] Government grants and tax credits. Minimum Minimum [Member] Outside basis difference in foreign subsidiary Deferred Tax Liabilities, Outside Basis Difference Deferred Tax Liabilities, Outside Basis Difference Royalties Royalty [Member] Adoption Date Trading Arrangement Adoption Date 2 to 3 years Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three Deferred revenue (note 11) Contract with Customer, Liability, Noncurrent Liquidity Risk Liquidity Risk, Policy [Policy Text Block] Liquidity Risk, Policy Impairment of Long-Lived Assets Impairment Of Long Lived Assets [Policy Text Block] Impairment Of Long Lived Assets Policy Text Block. Issuance of common stock in connection with At-The-Market ("ATM") sale (note 10a) Stock Issued During Period, Value, New Issues, At-The-Market Program, Net Of Issuance Costs Stock Issued During Period, Value, New Issues, At-The-Market Program, Net Of Issuance Costs Kairos Acquisition Kairos Acquisition [Member] Kairos Acquisition Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Tax Period [Axis] Tax Period [Axis] Option fee, total Option Fee, Total Option Fee, Total Exercise Price Award Exercise Price Schedule of Significant Components of the Deferred Income Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Arrangement Duration Trading Arrangement Duration Eligible to Receive Scenario, Plan [Member] Issuance of common stock through employee stock purchase plan (note 10g) Proceeds from Issuance of Shares Under Employee Share Purchase Plan Amount of cash inflow from issuance of shares under share-based compensation arrangement. Issuance includes, but is not limited to, employee share purchase plan. License And Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement Non-capital losses Operating Loss Carryforwards Leases Lessee, Finance Leases [Text Block] IPR&D and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Schedule Of Accounting Policies [Line Items] Schedule Of Accounting Policies [Line Items] Schedule of accounting policies. Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Excise tax on repurchase of common stock Excise tax on share repurchases Share Repurchase Program, Excise Tax Total finance lease liabilities Finance Lease, Liability All Individuals All Individuals [Member] Collaborative arrangement, royalty percentage Collaborative Arrangement, Royalty Percentage Collaborative Arrangement, Royalty Percentage Building Building [Member] Maximum exposure to credit risk for accounts receivable Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure Temporary Equity [Line Items] Temporary Equity [Line Items] Credit Concentration Risk Credit Concentration Risk [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Buy down payment Collaborative Arrangement, Buy Down Payment Collaborative Arrangement, Buy Down Payment Other Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Issuance of common stock on exercise of stock options (note 10f) Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Tax Year 2035 Tax Year Two Thousand Thirty Five [Member] Tax Year Two Thousand Thirty Five [Member] Tax Year 2033 Tax Year Two Thousand Thirty Three [Member] Tax Year Two Thousand Thirty Three [Member] Accounts payable and accrued liabilities (note 9) Total Accounts Payable and Accrued Liabilities, Current Commercial and Development Milestones Commercial and Development Milestones [Member] Commercial and Development Milestones [Member] Milestone revenue Performance Milestone [Member] Performance Milestone [Member] Janssen Biotech, Inc. Janssen [Member] Janssen [Member] Deferred tax liability (note 13)  Deferred tax liabilities Deferred Income Tax Liabilities, Net Technology Access Fee Technology Service [Member] Change in fair value of investments in equity instruments Unrealized Gain (Loss) on Investments Schedule of RSU Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Issuance of common stock for retracted exchangeable shares (in shares) Conversion of Stock, Shares Converted Share Repurchase Program [Domain] Share Repurchase Program [Domain] Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Debt securities, unrealized gain (loss) Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Maturity, Allocated and Single Maturity Date, Year One Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Maturity, Allocated and Single Maturity Date, Year One Measure: Measure [Axis] Increases related to current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Asset Class [Domain] Asset Class [Domain] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Issuance of common shares and pre-funded warrants in connection with public offering, net of offering costs (notes 10a and 10d) (in shares) Number of common shares issued (in shares) Stock Issued During Period, Shares, New Issues Operating lease liabilities Increase Decrease in Operating Lease Liabilities Increase decrease in operating lease liabilities. Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag Impairment Of Intangible Asset, Indefinite-Lived, Excluding Goodwill, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table] Schedule of Acquired Indefinite-Lived Intangible Assets by Major Class [Table] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Schedule of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Options forfeited and cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Items not involving cash: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Change in fair value of contingent consideration liability (note 15) Change in contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Number of options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Tax Year 2032 Tax Year Two Thousand Thirty Two [Member] Tax Year Two Thousand Thirty Two [Member] Statement [Table] Statement [Table] Glaxo Smith Kline Intellectual Property Development Ltd Glaxo SmithKline Intellectual Property Development Ltd [Member] Glaxo smith kline intellectual property development. Counterparty Name [Axis] Counterparty Name [Axis] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] The Redomicile Transactions (note 1, note 10b) (in shares) Stock Issued During Period, Shares, Exchange Of Shares Per The Redomiciliation Stock Issued During Period, Shares, Exchange Of Shares Per The Redomiciliation Level 1 Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Total current assets Assets, Current Statement of Cash Flows [Abstract] ZW171 ZW171 [Member] ZW171 Liability at the beginning of the period Liability at end of the period Contingent Consideration Liability Fair Value Disclosure Contingent Consideration Liability Fair Value Disclosure Short-term marketable securities: Available-for-Sale Securities, Debt Maturities [Abstract] Supplemental disclosure of non-cash investing and finance items: Noncash Investing and Financing Items [Abstract] Tax Period [Domain] Tax Period [Domain] Schedule of Balance Sheet Classification of Lease Liabilities Schedule of Lease Liabilities Classification [Table Text Block] Schedule of lease liabilities classification. Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Collaboration agreement expense Collaboration Agreement Expense Collaboration Agreement Expense Income Taxes Income Tax Disclosure [Text Block] Non-deductible expenses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount Debt securities, amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, After Year One Through Three Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, After Year One Through Three Total lease liabilities Lease Liability Lease Liability Purchase and retirement of common stock (10c) (in shares) Retirement of treasury stock (in shares) Treasury Stock, Shares, Retired Change in recognition and measurement of tax positions Effective Income Tax Rate Reconciliation, Change In Recognition And Measurement Of Tax Positions, Amount Income tax reconciliation change in recognition and measurement of tax positions. Pre-Funded Warrant Pre-Funded Warrant [Member] Pre-Funded Warrant [Member] Inducement Plan Inducement Plan [Member] Inducement Plan Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Discount rate Operating Lease, Weighted Average Discount Rate, Percent Net cash (used in) / provided by financing activities Net Cash Provided by (Used in) Financing Activities Jazz: Jazz [Member] Jazz Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Intangible Assets Intangible Assets Disclosure [Text Block] Operating lease liability Deferred Tax Assets Operating Lease Liability Deferred tax assets, operating lease liability. Fair Value as of Grant Date Award Grant Date Fair Value Difference between domestic and foreign tax rate Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Aggregate intrinsic vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Level 2 Fair Value, Inputs, Level 2 [Member] Percentage interest in subsidiary sold Disposal Group, Subsidiary, Ownership Interest Sold Disposal Group, Subsidiary, Ownership Interest Sold Geographical [Domain] Geographical [Domain] Issuance of common stock and pre-funded warrants in connection with public offering, net of offering costs (note 10a and 10d) Stock Issued During Period, Value, New Issues Schedule of Stock-based Compensation Expense for Equity Classified Instruments Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Accrued research and development expenses Accrued Research Expenses Current Accrued research expenses, current. Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common shares, $0.00001 par value; 900,000,000 authorized shares of common stock at December 31, 2024 and December 31, 2023 (68,964,319 and 70,115,997 shares issued and outstanding at December 31, 2024 and 2023, respectively (note 10b). Common Stock, Value, Issued Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Stock-Based Compensation Stock Based Compensation [Policy Text Block] Stock Based Compensation. Within 1 year Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months Credit note for amendment of program Credit for Program Amendments [Member] Credit for Program Amendments Total Liabilities, Other than Long-Term Debt, Noncurrent Change during the period Indefinite-Lived Intangible Assets Acquired Other Deferred Tax Assets, Other Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Net monetary liabilities denominated in foreign currency Net Monetary Liabilities Denominated In Foreign Currency Net Monetary Liabilities Denominated In Foreign Currency All Currencies [Domain] All Currencies [Domain] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Preferred shares, $0.00001 par value; 100,000,000 authorized shares of preferred stock, out of which, one share of preferred stock is a share of Special Voting Preferred Stock and outstanding as of December 31, 2024 and December 31, 2023 (note 10b). Preferred Stock, Value, Issued Total amount contributed by ESPP participants Contributions To Employee Share Purchase Plan contributions to employee share purchase plan. Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Gross deferred tax liabilities Deferred Tax Liabilities, Gross Development support payments Research Support Payments And Other Service [Member] Research support payments and other [member] Basic (in dollars per share) Net (loss) income per common share – basic (in dollars per share) Earnings Per Share, Basic Tax Year 2039 Tax Year 2039 [Member] Tax Year 2039. Proceeds from issuance of common stock under at-the-market program and from public offerings, net of issuance costs (notes 10a) Proceeds from Issuance of Common Stock Cash paid for measurement of operating lease liabilities Operating Lease, Payments Cash and Cash Equivalents Cash and Cash Equivalents [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Impairment on IPR&D (note 6) Impairment of acquired IPR&D (note 6) Impairment on acquired IPR&D Impairment on IPR&D (note 6) Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Acquisition of property and equipment and intangible assets in accounts payable and accrued liabilities Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Unrealized Gain (Loss) Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Maturity, Allocated and Single Maturity Date, After Year One Through Four Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Maturity, Allocated and Single Maturity Date, After Year One Through Four Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] IPR&D Deferred Tax Liabilities, Intangible Assets 2023 ATM Financing 2023 ATM Financing [Member] 2023 ATM Financing Total current liabilities Liabilities, Current Share Repurchase Program [Axis] Share Repurchase Program [Axis] Schedule of Revenue Recognized from Strategic Partnerships Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Over-Allotment Option Over-Allotment Option [Member] Schedule of Assets Measured at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Share issuance costs Deferred Tax Assets Share Issue Costs Deferred tax assets share issue costs. Weighted average estimated period for achievement of milestones Business Combination, Contingent Consideration, Term Business Combination, Contingent Consideration, Term Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Warrant exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Exchangeable shares, no par value, 570,637 issued and outstanding shares at December 31, 2024 (December 31, 2023: 651,219) (note 10b). Exchangeable Shares, Value, Issued Exchangeable Shares, Value, Issued Repurchase Program Repurchase Program [Member] Repurchase Program U.S Dollar Under the New Option Stock Plan U S dollars under the New Stock Option Plan [Member] Us dollars under the new stock option plan. Entity Address, City or Town Entity Address, City or Town Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Table] Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards Table [Table] Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Table] Leases Lessee, Leases [Policy Text Block] Schedule of Stock Options Granted Share-Based Payment Arrangement, Option, Activity [Table Text Block] Option exercised intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Compensation charge Share-based payment arrangement, expense Stock-based compensation expense Share-Based Payment Arrangement, Expense Issuance of common stock upon exercise of pre-funded warrants (note 10d) Stock Issued During Period, Value, Conversion of Convertible Securities Other Commitments [Table] Other Commitments [Table] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Institutional investors penalty, threshold percentage Share-Based Payment Arrangement, Institutional Investors Penalty, Threshold Percentage Share-Based Payment Arrangement, Institutional Investors Penalty, Threshold Percentage Business Acquisition [Axis] Business Acquisition [Axis] Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Document Fiscal Year Focus Document Fiscal Year Focus Treasury stock repurchased value Approximate value of shares purchased Treasury Stock, Value, Acquired, Cost Method Assets measured at fair value Assets, Fair Value Disclosure Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Current portion included in other current liabilities Finance Lease, Liability, Current Total operating lease payments Lessee, Operating Lease, Liability, to be Paid Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Asset Class [Axis] Asset Class [Axis] Insider Trading Arrangements [Line Items] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Three Finite-Lived Intangible Asset, Expected Amortization, after Year Three Debt securities, available-for-sale, amortized cost, excluding accrued interest, before allowance for credit loss Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss Issuance of common stock in connection with At-The-Market ("ATM") sale (note 10a) (in shares) Stock Issued During Period, Shares, New Issues, At-The-Market Program, Net of Issuance Costs Stock Issued During Period, Shares, New Issues, At-The-Market Program, Net of Issuance Costs Daiichi Sankyo, Co., Ltd Daiichi Sankyo, Co., Ltd [Member] Daiichi sankyo, co., ltd. Patents and Intellectual Property Costs Patents And Intellectual Property Costs [Policy Text Block] Patents and intellectual property costs policy. Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Customer [Domain] Customer [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Current Reporting Status Entity Current Reporting Status Accumulated deficit Retained Earnings [Member] Schedule of Other Long-Term Liabilities Other Noncurrent Liabilities [Table Text Block] Expense for other preclinical and research programs Other Preclinical And Research Programs [Member] Other Preclinical And Research Programs Derivative Liability Roll Forward [Roll Forward] Derivative Liability Roll Forward [Roll Forward] Derivative Liability Roll Forward Income Tax Disclosure [Table] Income Tax Disclosure [Table] Income Tax Disclosure [Table] Options vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Debt securities, unrealized gain (loss) Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Termination of long-term facility lease in Seattle, net Operating Lease Termination Operating Lease Termination Schedule of Income Tax Expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Company Selected Measure Name Company Selected Measure Name Milestone and Other Payments Milestone and Other Payments [Member] Milestone and other payments [member] Accounts Payable and Accrued Liabilities